Key Highlights

  • Shares are trading at $10.14, up 15.92% in Friday's session.
  • The Hong Kong Intellectual Property Department granted a Patent for the company's proprietary platform technology used in CyPath Lung, its noninvasive lung cancer diagnostic.
  • The grant follows a 2025 patent from China, giving the company dual intellectual property protection in a region that accounts for nearly two-thirds of lung cancer cases worldwide.
  • In a published clinical trial, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in high-risk patients with small lung nodules.

Hong Kong Patent Strengthens Asia Market Positioning

bioAffinity Technologies (NASDAQ:BIAF) shares climbed sharply in Friday's session after the Hong Kong Intellectual Property Department granted a patent covering the company's proprietary platform technology for predicting the likelihood of lung cancer using flow cytometry and fluorescent markers in sputum. bioAffinity Technologies is a San Antonio, Texas-based biotechnology company focused on developing noninvasive healthcare solutions for the early detection and monitoring of lung disease.

The Hong Kong patent, titled System and Method for Determining Lung Health, complements a 2025 patent granted in China, giving the company dual intellectual property protection in a region that accounts for nearly two-thirds of lung cancer cases worldwide and an estimated 1.6 million new diagnoses annually.

CyPath Lung's Clinical Performance Underpins the Opportunity

The patented technology is the scientific foundation underlying CyPath Lung, which uses advanced flow cytometry and proprietary artificial intelligence to identify cell populations in patient sputum that indicate malignancy. In a published clinical trial of high-risk patients with small indeterminate lung nodules under 20 millimeters, the test demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value.

Expanding Global Patent Estate Supports Broader Commercialization

The Hong Kong grant adds to a global patent estate that now covers multiple patents and pending applications across the United States, Australia, Canada, China, the European Union, Japan, Mexico, and Singapore, safeguarding the core technology that powers CyPath Lung and other diagnostics in the company's pipeline as it looks to expand internationally.